Gilead: Phase III studies of Letairis shows improved exercise capacity (Gilead Sciences)

        NEW YORK (Thomson Financial) - Gilead Sciences Inc. Thursday said Phase III
ARIES-1 and ARIES-2 studies of Letairis showed improved exercise capacity in
patients with pulmonary arterial hypertension functional Class II or III
symptoms.
    The ARIES-2 study also showed a delay in clinical worsening compared to
patients treated with a placebo, the compamny said.
    In the company's ARIES-E study, 43 of the 361 patients who enrolled in the
study discontinued before completing the 48 weeks of treatment. This includes 14
patients who died.
    Gilead said that the patients who discontinued had a more severe disease at
baseline.
    Shares of Gildead closed Wednesday at 453.57. The stock is up 30% over the
past 52 weeks.
Ryan Vlastelica
rv/vj

COPYRIGHT

Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.